Biggest pharma M&A deal of the year so far announced by Jazz Pharma

3 February 2021

Setting the scene for an active M&A year for the biopharma sector, US biotech firm Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the biggest takeover deal so far this year.

America-traded shares of UK medical cannabis-based products GW Pharmaceuticals (Nasdaq: GWPH) leapt more than 48% to $216.70, after it was revealed that its board had accepted an offer form Jazz Pharma, which is for $200.0 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. Jazz also edged up 0.9% pre-market, though it was down 2.9% by late morning

The transaction, which represents a 50% premium to GW’s closing price on Tuesday, has been unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2021

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK